Showing 1196 results
- Media Release /Phase III data showed median overall survival of 25.6 months in patients with BRAF+ V600E/K metastatic melanoma who received Tafinlar + Mekinist Tafinlar + Mekinist combination also demonstrated…
- Media Release /Eight of nine evaluable patients tested had no signs of CLL in their bone marrow at three months.CTL119 is a humanized CD19-directed CAR-T cell therapy being developed in collaboration with the…
- Media Release /In ALK-positive metastatic NSCLC patients, Zykadia median progression-free survival (PFS) was 16.6 months, compared to 8.1 months with chemotherapy[1] The overall intracranial response rate…
- Media Release /New analyses from the FLAME study suggest dual bronchodilator Ultibro® Breezhaler® provides similar or better efficacy versus steroid-containing therapies, regardless of blood eosinophil (a type of…
- Media Release /Phase III trial, first-line treatment with Zykadia resulted in improved progression-free survival (PFS) over SOC chemotherapy with maintenance, including in patients with brain metastases[1]…
- Media Release /Updated analyses from the Kisqali® pivotal Phase III MONALEESA-2 trial in hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer to be…
- Media Release /Better Hearts Better Cities is a Novartis Foundation initiative to improve cardiovascular health in low-income urban communities by addressing the prevention, management and control of hypertension…
- Media Release /Divestment includes Xiidra®, on-market treatment for dry eye disease and additional ophthalmic investigational therapiesNovartis advances strategy of focused portfolio and prioritized therapeutic…
- Media Release /Community Partnership Day symbolizes the company's commitment to improving people's lives and serving our local communities Follow the excitement with #NovartisCPD2017 and #proudmoments2017 via…
- Media Release /Exclusive license for emricasan supports rapidly growing development portfolio in chronic liver diseases, including NASH Conatus has initiated the Phase IIb ENCORE-LF clinical trial with…
Pagination
- ‹ Previous page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- …
- 120
- › Next page